Bromelain |
| Catalog No.GC62536 |
Bromelain은 플라즈마 키니노겐의 하향 조절, 프로스타글란딘 E2 발현의 억제, 고급 당화 최종 생성물 수용체의 분해 및 혈관신생 바이오마커의 조절 및 COX-경로 상류의 항산화 작용을 통해 작용하는 파인애플 줄기에서 추출한 항염증제입니다. .
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 9001-00-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Bromelain is an anti-inflammatory drug derived from pineapple stem that acts through down-regulation of plasma kininogen, inhibition of Prostaglandin E2 expression, degradation of advanced glycation end product receptors and regulation of angiogenic biomarkers as well as antioxidant action upstream in the COX-pathway[1]. Bromelain exhibits various fibrinolytic, antiedematous, antithrombotic, and anti-inflammatory activities. Bromelain also possesses some anticancerous activities and promotes apoptotic cell death[2].
Bromelain (40 mg/kg; intraperitoneal injection; daily; for 7 days; male Sprague-Dawley rats) pretreatment reduces the motor dysfunction in the parkinsonian rat model of parkinson’s disease (PD). 6-OHDA injection resulted in marked motor impairment which is prevented by pretreatment with Bromelain prior to the lesion[1].
[1]. Adu TS, et al. Effects of bromelain on motor responses following intra-medial forebrain bundle 6-OHDA injection in rat model of parkinsonism. Metab Brain Dis. 2019 Jul 22.
[2]. Pavan R, et al. Properties and therapeutic application of bromelain: a review. Biotechnol Res Int. 2012;2012:976203.
Average Rating: 5 (Based on Reviews and 3 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *